June 15, 2026
Perseus Proteomics Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Notice Regarding Patent Grant Based on Joint Research with Nagoya University — Grant of Patent for "Method for Determining Sensitivity or Medical Effect of Anti-Transferrin Receptor Antibody" —

We hereby announce that the following patent has been granted as a result of joint research with Nagoya University, Tokai National Higher Education and Research System, located in Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.

Title of Invention: Method for Determining Sensitivity or Medical Effect of Anti-Transferrin Receptor Antibody
Patent No.: 7875530
Registration Date: June 10, 2026
Patentees: Tokai National Higher Education and Research System;
Perseus Proteomics Inc.
Inventors: Hitoshi Kiyoi, Yuichi Ishikawa, Marie Nakashima
Nagoya University, Tokai National Higher Education and Research System
Junpei Oya, Aya Sakamoto, Yoshinori Ukai, Tadashi Matsuura, et al.
7875530

Details:
The research group at Nagoya University and the Company have been analyzing the mechanism by which anti-transferrin receptor antibodies inhibit the proliferation of cancer cells. This patent covers a method for determining sensitivity or medical effect of anti-transferrin receptor antibodies using intracellular iron levels as an objective indicator, as an outcome of this joint research.

Patent applications for this invention have been filed in multiple countries and regions, including Japan, the United States, Europe, and China. This patent has now been granted in Japan ahead of the other jurisdictions.

This matter will have no impact on the Company's earnings forecast for the current fiscal year. However, it is expected to contribute to enhancing the Company's corporate value over the medium to long term through future business development and other initiatives.

End

Glossary
Transferrin: A glycoprotein that binds to and transports iron in the blood. It is mainly produced in the liver and plays a role in delivering iron to cells in the body.